PetriKey

Antimicrobial

Isoniazid

KatG-activated mycolic acid synthesis blocker

eye-soh-NY-uh-zid

antimycobacterialprodrugmycolic-acidinhakatgtuberculosis

High-yield clue

Isoniazid is a prodrug activated by KatG that then inhibits InhA to block mycolic acid synthesis; katG loss is a classic resistance route.

Overview

A key antimycobacterial prodrug studied for blocking mycolic acid synthesis after activation by the mycobacterial catalase-peroxidase KatG.

Classification

  • Antimycobacterial prodrug
  • Activated by KatG catalase-peroxidase
  • Inhibits InhA (enoyl-ACP reductase)
  • Blocks mycolic acid synthesis

Lab & identification clues

  • Forms INH-NAD adduct inhibiting InhA concept
  • katG mutation resistance vocabulary
  • inhA promoter mutation cross-resistance concept

Associations

  • Latent and active tuberculosis study vocabulary
  • Pyridoxine (B6) depletion / neuropathy concept
  • Hepatotoxicity monitoring study framing

Commonly confused with

  • Rifamycins
  • Ethambutol

Your notes

Original mechanism summary for microbiology study. Sources checked: CDC antimicrobial-resistance guidance, NCBI Bookshelf Medical Microbiology, and standard coursework frameworks; reviewed 2026-06. Covers class, mechanism, and resistance vocabulary only; no prescribing, dosing, or patient-specific treatment guidance.

CDC: CDC antimicrobial resistance overview and threat reportssourceWHO: WHO bacterial priority pathogens list 2024sourceNCBI Bookshelf: Medical Microbiology antimicrobial mechanism foundationssource